Financial Symmetry’s Vertex Pharmaceuticals VRTX Stock Holding History

Financial Symmetry’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$378K	Hold	760	–	–	0.13%	44
2026 Q1	$325K	Buy	760 +5	+0.7%	+$2.33K	0.12%	45
2025 Q4	$342K	Hold	755	–	–	0.14%	42
2025 Q3	$296K	Hold	755	–	–	0.13%	42
2025 Q2	$336K	Hold	755	–	–	0.17%	34
2025 Q1	$366K	Hold	755	–	–	0.23%	30
2024 Q4	$304K	Hold	755	–	–	0.21%	32
2024 Q3	$351K	Hold	755	–	–	0.25%	32
2024 Q2	$354K	Hold	755	–	–	0.28%	28
2024 Q1	$316K	Hold	755	–	–	0.28%	28
2023 Q4	$307K	Buy	+755	New	+$279K	0.3%	24

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Financial Symmetry's VRTX Position: Q2 2026 in Review

Financial Symmetry held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 760 shares worth $378K. The position accounts for 0.13% of the portfolio, ranked #44.

Financial Symmetry first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Financial Symmetry held 760 shares of Vertex Pharmaceuticals worth $378K as of Q2 2026.
Financial Symmetry left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.13% of Financial Symmetry's portfolio in Q2 2026, its #44 holding.
Financial Symmetry first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Financial Symmetry's 13F filing for Q2 2026, filed 14 Jul 2026.